

Office of Public Affairs, Headquarters Washington, DC. 20555-0001 www.nrc.gov • opa.resource@nrc.gov

NRC NEW

No: 23-012 CONTACT: <u>Scott Burnell</u>, 301-415-8200 February 27, 2023

NRC Issues Final Safety Evaluation Report for SHINE Medical Technologies Operating License

ଁ (ତ) 🕇

Nuclear Regulatory Commission staff have completed their <u>Final Safety Evaluation</u> <u>Report</u> on SHINE Medical Technology LLC's application for a license to operate a medical isotope production facility in Janesville, Wisconsin. The report concludes there are no safety aspects that would preclude issuing the license for operation of the facility.

The staff finalized the <u>Supplemental Environmental Impact Statement</u> regarding the SHINE application on Jan. 31, 2023. The agency will consider both documents in deciding whether to issue the license.

SHINE filed the application on July 17, 2019, seeking the license to operate the facility, currently under construction in Janesville. The facility would create molybdenum-99, which subsequently produces technetium-99m, an isotope used in over 30 different diagnostic medical imaging procedures. Information concerning the operating license review, with proprietary details removed, is available on the <u>NRC website</u>.